- Study: Whooping cough vaccine may not prevent infection
- Study: Pharmacist intervention improves shingles vaccine rate
- Chickenpox vaccine does not appear to increase incidence of shingles, study finds
- FDA approves one-week antifungal drug made by Valeant
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
ST. PAUL, Minn. — 3M's skin and wound care division has launched an easy-to-apply cream that is designed to relieve skin discomforts caused by fungal infections.
New Cavilon antifungal cream, which is available in 2-oz. and 5-oz. tubes, is enriched with water-repelling ingredients, including 2% miconazole nitrate, an active ingredient that has been clinically proven to treat tinea corporis (ringworm), tinea pedis (athlete’s foot) and tinea cruris (jock itch), 3M said. The product also is approved for use on fungal infections caused by Candida albicans.
“Cavilon antifungal cream fills a significant need for clinicians and their patients, and by launching this new product, 3M is reinforcing its strong commitment to skin care,” said Marcello Napol, global business director of 3M skin and wound care. “It also bolsters our Cavilon brand by meeting clinical needs for all types of skin applications.”